How do NSAIDs close a PDA?

How NSAIDs Help Close a PDA in Newborns

Patent ductus arteriosus (PDA) is a common condition in premature infants, where the ductus arteriosus—a blood vessel connecting the pulmonary artery and aorta—fails to close after birth. In many cases, this open vessel can lead to complications like heart failure or respiratory distress, requiring prompt medical intervention.

One effective, non-surgical approach involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or indomethacin. These medications work by targeting a key biological pathway: they inhibit the enzyme cyclooxygenase, which is responsible for producing prostaglandins. Prostaglandins, especially prostaglandin E2, play a crucial role in keeping the ductus arteriosus open during fetal life. By reducing their levels, NSAIDs remove the chemical signal that keeps the vessel open, allowing it to constrict and close functionally.

This method successfully achieves closure in up to 80% of treated infants, making NSAIDs a preferred first-line therapy in many neonatal intensive care units. The treatment is especially effective in preterm babies, whose ductus arteriosus is more sensitive to prostaglandin levels and more responsive to pharmacological intervention.

Compared to surgical ligation, NSAID therapy is less invasive and avoids the risks associated with surgery. However, careful monitoring is required, as these drugs can affect kidney function and platelet activity in vulnerable newborns. Not every infant responds the same way, and in some cases, additional interventions may still be necessary.

While the mechanism is well understood, ongoing research continues to refine dosing strategies and identify which patients are most likely to benefit. Still, the use of NSAIDs represents a major advancement in neonatal care—offering a simple, effective solution rooted in the body’s own physiology.